|
PIGK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62725388719309E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.31636973227978E-14 |
| Normal-vs-Stage2 |
6.40199999999425E-05 |
| Normal-vs-Stage3 |
4.94515539628537E-12 |
| Normal-vs-Stage4 |
2.1976864772455E-12 |
| Stage1-vs-Stage2 |
1.600360E-01 |
| Stage1-vs-Stage3 |
1.589250E-01 |
| Stage1-vs-Stage4 |
1.072270E-02 |
| Stage2-vs-Stage3 |
4.405600E-02 |
| Stage2-vs-Stage4 |
4.278500E-03 |
| Stage3-vs-Stage4 |
1.754590E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.230700E-04 |
| Normal-vs-Asian |
5.69089999569172E-08 |
| Caucasian-vs-AfricanAmerican |
1.106180E-01 |
| Caucasian-vs-Asian |
4.223800E-01 |
| AfricanAmerican-vs-Asian |
4.175600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.48245868306185E-13 |
| Normal-vs-Female |
1.76036962784565E-12 |
| Male-vs-Female |
2.404200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.08644213017806E-12 |
| Normal-vs-Age(41-60Yrs) |
4.05675493198032E-12 |
| Normal-vs-Age(61-80Yrs) |
3.41380035351335E-10 |
| Normal-vs-Age(81-100Yrs) |
8.656700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.482600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.198000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.711200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.652000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.848200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.772400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.256600E-03 |
| Classical-VS-Follicular |
3.455200E-01 |
| Classical-VS-Other |
2.485800E-01 |
| Classical-VS-Normal |
1.69608771471985E-12 |
| Tall-VS-Follicular |
5.637900E-03 |
| Tall-VS-Other |
9.145800E-01 |
| Tall-VS-Normal |
1.63989932744357E-11 |
| Follicular-VS-Other |
2.175000E-01 |
| Follicular-VS-Normal |
7.48249999960038E-07 |
| Other-VS-Normal |
4.406800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.71179761873941E-11 |
| Normal-vs-N1 |
4.70179450928754E-13 |
| N0-vs-N1 |
1.568350E-02 |
|
|
